Insmed (INSM) Net Cash Flow (2010 - 2026)
Insmed (INSM) posted quarterly Net Cash Flow of $72.3 million for Q1 2026, up 147.35% year-over-year from $29.2 million in Q1 2025, and down 58.85% quarter-over-quarter from $175.7 million in Q4 2025.
Insmed (INSM) Net Cash Flow (2010 - 2026) Analysis & Trends
Insmed's Net Cash Flow history runs 17 years deep, the most recent figure standing at $72.3 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 147.35% year-over-year to $72.3 million; the TTM figure through Mar 2026 stood at $179.5 million (up 192.97% YoY), while the FY2025 annual figure was -$45.5 million, down 161.54% from the prior year.
- Net Cash Flow for Q1 2026 stood at $72.3 million, down from $175.7 million in the prior quarter.
- The five-year high for Net Cash Flow was $880.1 million in Q2 2025, with the low at -$948.6 million in Q3 2025.
- The 5-year median for Net Cash Flow is -$5.8 million (2023), against an average of -$7.8 million.
- The sharpest annual moves came in 2023 and 2024: Net Cash Flow slumped 3783.94% in 2023, then soared 1752.77% in 2024.
- Insmed's Net Cash Flow stood at $660.5 million in 2022, then sank by 100.87% to -$5.8 million in 2023, then jumped by 1752.77% to $95.1 million in 2024, then surged by 84.76% to $175.7 million in 2025, then sank by 58.85% to $72.3 million in 2026.
- Business Quant data shows INSM's Net Cash Flow at $72.3 million in Q1 2026, $175.7 million in Q4 2025, and -$948.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -170.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37.14 Mn |
| Jun 30, 2026 | -37.14 Mn |
| Mar 31, 2026 | 72.30 Mn |
| Mar 31, 2026 | 72.30 Mn |
| Dec 31, 2025 | 175.67 Mn |
| Dec 31, 2025 | 175.67 Mn |
| Sep 30, 2025 | -948.58 Mn |
| Sep 30, 2025 | -948.58 Mn |
| Jun 30, 2025 | 880.07 Mn |
| Jun 30, 2025 | 880.07 Mn |
| Mar 31, 2025 | -152.68 Mn |
| Mar 31, 2025 | -152.68 Mn |
| Dec 31, 2024 | 95.08 Mn |
| Dec 31, 2024 | 95.08 Mn |
| Sep 30, 2024 | -787.19 Mn |
| Sep 30, 2024 | -787.19 Mn |
| Jun 30, 2024 | 651.76 Mn |
| Jun 30, 2024 | 651.76 Mn |
| Mar 31, 2024 | 114.31 Mn |
| Mar 31, 2024 | 114.31 Mn |